Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Ballester

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinical Endocrinology|August 1, 1995
Effect of haemoglobin and endogenous erythropoietin on hypothalamic-pituitary thyroidal and gonadal secretion: an analysis of anaemic (high EPO) and polycythaemic (low EPO) patientsG Ramirez, P A Bittle, H A Rabb, et al.
Seminars in Oncology|October 1, 1993
The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleedingK Benson, K Fields, J Hiemenz, et al.
Bone Marrow Transplantation|August 6, 1999
Collection of peripheral blood progenitor cells (PBPC) based on a rising WBC and platelet count significantly increases the number of CD34+ cellsM S Krieger, G Schiller, J R Berenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study GroupJ R Berenson, A Lichtenstein, L Porter, et al.
The New England Journal of Medicine|February 22, 1996
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study GroupJ R Berenson, A Lichtenstein, L Porter, et al.
Blood|March 9, 1999
Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myelomaR Vescio, G Schiller, A K Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trialA K Stewart, R Vescio, G Schiller, et al.
Bone Marrow Transplantation|February 16, 2000
Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patientsR A Vescio, C H Wu, L Zheng, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinical Endocrinology|August 1, 1995
Effect of haemoglobin and endogenous erythropoietin on hypothalamic-pituitary thyroidal and gonadal secretion: an analysis of anaemic (high EPO) and polycythaemic (low EPO) patientsG Ramirez, P A Bittle, H A Rabb, et al.
Seminars in Oncology|October 1, 1993
The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleedingK Benson, K Fields, J Hiemenz, et al.
Bone Marrow Transplantation|August 6, 1999
Collection of peripheral blood progenitor cells (PBPC) based on a rising WBC and platelet count significantly increases the number of CD34+ cellsM S Krieger, G Schiller, J R Berenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study GroupJ R Berenson, A Lichtenstein, L Porter, et al.
The New England Journal of Medicine|February 22, 1996
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study GroupJ R Berenson, A Lichtenstein, L Porter, et al.
Blood|March 9, 1999
Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myelomaR Vescio, G Schiller, A K Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trialA K Stewart, R Vescio, G Schiller, et al.
Bone Marrow Transplantation|February 16, 2000
Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patientsR A Vescio, C H Wu, L Zheng, et al.
Pageof 1